Targeting platelet thrombin receptor signaling to prevent thrombosis.

Abstract

Platelets contribute fundamentally to ischemic heart disease, and antiplatelet therapy has been critical to reducing acute thrombotic complications of atherosclerotic disease. Thrombin, by acting on protease activated receptors (PAR), is one of the most potent platelet activators. PAR-1 antagonists may therefore provide more comprehensive antithrombotic effects. We review the pathophysiology of atherothrombosis, platelet activation by thrombin, the role of platelet protease activated receptors (PAR), and the clinical data supporting their use.

• Authors: Eric L Wallace, Susan S Smyth
• Journal: Pharmaceuticals (Basel, Switzerland) (Pharmaceuticals (Basel)) Vol. 6 Issue 8 Pg. 915-28 (Aug 02 2013) ISSN: 1424-8247 [Print] Switzerland
• PMID: 24276376 (Publication Type: Journal Article)